A cobalt-containing acidic amino acid complex and its use for treating cancer
US-2024398829-A1 · Dec 5, 2024 · US
Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US9566257B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9566257-B2 |
| Application number | US-201213495966-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 13, 2012 |
| Priority date | Nov 26, 2004 |
| Publication date | Feb 14, 2017 |
| Grant date | Feb 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising ornithine or a physiologically acceptable salt thereof and at least one of phenylacetate or phenylbutyrate or a physiologically acceptable salt thereof, wherein the composition comprises no other amino acid, wherein the ornithine and at least one of phenylacetate or phenylbutyrate are in a weight ratio from 2:1 to 1:2, wherein the composition is formulated for oral administration. 2. The pharmaceutical composition of claim 1 , wherein the ornithine and at least one of phenylacetate or phenylbutyrate are in a weight ratio of about 1:1. 3. The pharmaceutical composition of claim 1 , comprising from 1 g to 50 g of ornithine and from 1 g to 50 g of phenylacetate or phenylbutyrate. 4. The pharmaceutical composition of claim 1 , comprising from 5 g to 30 g of ornithine and from 5 g to 30 g of phenylacetate or phenylbutyrate. 5. The pharmaceutical composition of claim 1 , comprising a physiologically acceptable salt of ornithine and a physiologically acceptable salt of at least one of phenylacetate or phenylbutyrate. 6. The pharmaceutical composition of claim 5 , comprising ornithine hydrochloride and at least one of sodium phenylacetate or sodium phenylbutyrate. 7. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier or diluent. 8. The pharmaceutical composition of claim 7 , comprising sterile water. 9. A pharmaceutical composition consisting of ornithine or a physiologically acceptable salt thereof, at least one of phenylacetate or phenylbutyrate or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the composition is formulated for oral administration.
Assignees
Inventors
Classifications
Antihypertensives · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9566257B2 cover?
- The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine f…
- Who is the assignee on this patent?
- Jalan Rajiv, Jalan Kamal Nayan, Ucl Business Plc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/198. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).